{"nctId":"NCT03091673","briefTitle":"Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients","startDateStruct":{"date":"2017-03-27","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 1"],"count":31,"armGroups":[{"label":"G-Pen (glucagon injection) 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Glucagon"]},{"label":"G-Pen (glucagon injection) 1.0 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Glucagon"]}],"interventions":[{"name":"Glucagon","otherNames":["G-Pen (glucagon injection)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* diagnosed with T1D for at least 6 months at Screening.\n* current usage of daily insulin treatment.\n\nExclusion Criteria:\n\n* pregnant or nursing\n* renal insufficiency\n* hepatic synthetic insufficiency\n* aspartate or alanine aminotransferase \\> 3 times the upper limit of normal\n* hematocrit less than or equal to 30%\n* use of \\> 2.0 U/kg total insulin dose per day\n* inadequate venous access\n* current seizure disorder\n* history of pheochromocytoma or disorder with increased risk of pheochromocytoma\n* history of insulinoma\n* history of glycogen storage disease.\n* active use of alcohol or drugs of abuse\n* administration of glucagon within 14 days of the first treatment visit\n* participation in other studies involving an investigational drug or device within 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Plasma Glucose","description":"The primary endpoint for this study is an evaluation of change in plasma glucose following treatment with G-Pen, with an emphasis on the increase from baseline to 30 minutes post-dosing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.4","spread":"18.3"},{"groupId":"OG001","value":"84.2","spread":"25.3"},{"groupId":"OG002","value":"54.0","spread":"27.3"}]}]}]},{"type":"SECONDARY","title":"Time for Plasma Glucose to Increase by ≥25 mg/dL","description":"Time for plasma glucose to increase by ≥25 mg/dL from baseline will be analyzed descriptively for each age cohort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"3.78"},{"groupId":"OG001","value":"16.2","spread":"4.63"},{"groupId":"OG002","value":"26.6","spread":"9.51"}]}]}]},{"type":"SECONDARY","title":"Plasma Glucagon Area Under the Curve","description":"Plasma glucagon area under the curve (AUC) for each age cohort will be analyzed descriptively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14440.8","spread":"2114.9"},{"groupId":"OG001","value":"14392.3","spread":"2698.4"},{"groupId":"OG002","value":"13105.5","spread":"13105.45"}]}]}]},{"type":"SECONDARY","title":"Plasma Glucagon Cmax","description":"Plasma glucagon maximum concentration for each age cohort will be analyzed descriptively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202.3","spread":"35.9"},{"groupId":"OG001","value":"216.3","spread":"51.2"},{"groupId":"OG002","value":"199.0","spread":"57.0"}]}]}]},{"type":"SECONDARY","title":"Plasma Glucagon Tmax","description":"Plasma glucagon time to maximum concentration for each age cohort will be analyzed descriptively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.6","spread":"10.5"},{"groupId":"OG001","value":"68.5","spread":"15.3"},{"groupId":"OG002","value":"81.2","spread":"14.9"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Nausea","Hypoglycemia","Vomiting","Hyperglycemia","Headache"]}}}